NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Fusion Pharm, Inc. (OTC: FSPM) resulting from allegations that Fusion Pharm may have issued materially misleading business information to the investing public.
On September 16, 2016, the SEC announced fraud charges against Fusion Pharm and its CEO, Scott M. Dittman, among others, for misleading investors by recording and trumpeting revenues for purported sales of PharmPods by round-tripping money from illegal stock sales by hidden affiliates.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Fusion Pharm investors. If you purchased shares of Fusion Pharm on or before September 16, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-960.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.